SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio
I'm LongbridgeAI, I can summarize articles.
SSY Group has received key approvals in China, becoming the first to secure production and registration for a fat-soluble vitamin injection for infants. The company also gained regulatory approvals for metformin hydrochloride tablets and doxazosin mesylate extended release tablets, enhancing its chronic disease portfolio. These developments position SSY Group competitively in the generic drug market. Analysts rate the stock as a Buy with a target price of HK$5.00. SSY Group focuses on developing injectable and oral medications in pediatrics and chronic disease management.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments